Rare focus, global ambition: Neurizon’s next chapter in ALS

Australian biotech Neurizon Therapeutics (ASX: NUZ) is setting out to redefine how neurodegenerative diseases are treated, positioning itself as a rare-disease innovator in a space long starved of effective therapies.

The Melbourne-based company, previously known as PharmAust, recently secured a regulatory milestone with US Food and Drug Administration (FDA) clearance to enter the Phase II/III HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS), supported by Institutional Review Board (IRB) approval at participating trial sites.

At the center of the push is chief executive Dr Michael Thurn, a former regulator at Australia’s Therapeutic Goods Administration (TGA), whose career path has given him a broad view of drug development. “I’ve worked on more than a dozen IND applications, across my career,” he says. “What matters most is entering the clinic with a robust data package and strong alignment with regulators, and that’s where we are today”.